These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38768273)

  • 1. Type 1 Brugada Pattern May Be Provoked by Ajmaline in Some Healthy Subjects: Results From a Clinical Trial.
    Ensam B; Scrocco C; Johnson D; Wijeyeratne YD; Bastiaenen R; Gray B; Miles C; Ben-Haim Y; Papatheodorou S; Sharma S; Papadakis M; Devine B; Macfarlane PW; Behr ER
    Circulation; 2024 May; 149(21):1693-1695. PubMed ID: 38768273
    [No Abstract]   [Full Text] [Related]  

  • 2. Ajmaline attenuates electrocardiogram characteristics of inferolateral early repolarization.
    Roten L; Derval N; Sacher F; Pascale P; Wilton SB; Scherr D; Shah A; Pedersen ME; Jadidi AS; Miyazaki S; Knecht S; Hocini M; Jaïs P; Haïssaguerre M
    Heart Rhythm; 2012 Feb; 9(2):232-9. PubMed ID: 21914496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome.
    Cheung CC; Mellor G; Deyell MW; Ensam B; Batchvarov V; Papadakis M; Roberts JD; Leather R; Sanatani S; Healey JS; Chauhan VS; Birnie DH; Champagne J; Angaran P; Klein GJ; Yee R; Simpson CS; Talajic M; Gardner M; Yeung-Lai-Wah JA; Chakrabarti S; Laksman ZW; Sharma S; Behr ER; Krahn AD
    JACC Clin Electrophysiol; 2019 Apr; 5(4):504-512. PubMed ID: 31000106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ajmaline infusion during automated screening in Brugada syndrome and spontaneous Type 1 electrocardiogram unmasks non-suitability for subcutaneous implantable cardioverter-defibrillator.
    Özkartal T; Auricchio A; Conte G
    Eur Heart J; 2019 Jun; 40(23):1888-1889. PubMed ID: 30793741
    [No Abstract]   [Full Text] [Related]  

  • 5. Time to positivity of diagnostic provocative pharmacologic testing in Brugada syndrome.
    Saglietto A; Martinengo E; Cerrato N; Bergamasco L; Castagno D; Gaita F; De Ferrari GM; Giustetto C
    Heart Rhythm; 2023 Jan; 20(1):144-145. PubMed ID: 36064038
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug challenge with sodium-channel blockade: improving phenotypic characterization of early repolarization.
    Ilkhanoff L; Knight BP
    Heart Rhythm; 2012 Feb; 9(2):240-1. PubMed ID: 21964324
    [No Abstract]   [Full Text] [Related]  

  • 7. Life-threatening ventricular arrhythmias during ajmaline challenge in patients with Brugada syndrome: incidence, clinical features, and prognosis.
    Conte G; Sieira J; Sarkozy A; de Asmundis C; Di Giovanni G; Chierchia GB; Ciconte G; Levinstein M; Casado-Arroyo R; Baltogiannis G; Saenen J; Saitoh Y; Pappaert G; Brugada P
    Heart Rhythm; 2013 Dec; 10(12):1869-74. PubMed ID: 24055942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting cardiac electrical response to sodium-channel blockade and Brugada syndrome using polygenic risk scores.
    Tadros R; Tan HL; ; El Mathari S; Kors JA; Postema PG; Lahrouchi N; Beekman L; Radivojkov-Blagojevic M; Amin AS; Meitinger T; Tanck MW; Wilde AA; Bezzina CR
    Eur Heart J; 2019 Oct; 40(37):3097-3107. PubMed ID: 31504448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current-to-load mismatch, Brugada ECG pattern, and the associated arrhythmogenesis.
    Di Diego JM
    Heart Rhythm; 2011 Jan; 8(1):119-20. PubMed ID: 20920601
    [No Abstract]   [Full Text] [Related]  

  • 10. Insight into the mechanism of Brugada syndrome: epicardial substrate and modification during ajmaline testing.
    Sacher F; Jesel L; Jais P; Haïssaguerre M
    Heart Rhythm; 2014 Apr; 11(4):732-4. PubMed ID: 23732228
    [No Abstract]   [Full Text] [Related]  

  • 11. A Report of Brugada Syndrome Presenting with Cardiac Arrest Triggered by Verapamil Intoxication.
    Yakut K; Erdoğan İ; Varan B; Atar İ
    Balkan Med J; 2017 Dec; 34(6):576-579. PubMed ID: 29215340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome.
    Wolpert C; Echternach C; Veltmann C; Antzelevitch C; Thomas GP; Spehl S; Streitner F; Kuschyk J; Schimpf R; Haase KK; Borggrefe M
    Heart Rhythm; 2005 Mar; 2(3):254-60. PubMed ID: 15851314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ajmaline challenge in young individuals with suspected Brugada syndrome.
    Sorgente A; Sarkozy A; De Asmundis C; Chierchia GB; Capulzini L; Paparella G; Henkens S; Brugada P
    Pacing Clin Electrophysiol; 2011 Jun; 34(6):736-41. PubMed ID: 21303388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmasked Brugada pattern by ajmaline challenge in patients with myotonic dystrophy type 1.
    Pambrun T; Bortone A; Bois P; Degand B; Patri S; Mercier A; Chahine M; Chatelier A; Coisne D; Amiel A
    Ann Noninvasive Electrocardiol; 2015 Jan; 20(1):28-36. PubMed ID: 24943134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrical Substrate Elimination in 135 Consecutive Patients With Brugada Syndrome.
    Pappone C; Brugada J; Vicedomini G; Ciconte G; Manguso F; Saviano M; Vitale R; Cuko A; Giannelli L; Calovic Z; Conti M; Pozzi P; Natalizia A; Crisà S; Borrelli V; Brugada R; Sarquella-Brugada G; Guazzi M; Frigiola A; Menicanti L; Santinelli V
    Circ Arrhythm Electrophysiol; 2017 May; 10(5):e005053. PubMed ID: 28500178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The smartwatch detects ECG abnormalities typical of Brugada syndrome.
    Spaccarotella C; Santarpia G; Curcio A; Indolfi C
    J Cardiovasc Med (Hagerstown); 2021 Dec; 22(12):e24-e25. PubMed ID: 34054105
    [No Abstract]   [Full Text] [Related]  

  • 17. Ajmaline challenge: to stop or not to stop..
    Probst V; Le Marec H
    Heart Rhythm; 2009 May; 6(5):632-3. PubMed ID: 19389650
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.
    Maury P; Audoubert M; Cintas P; Rollin A; Duparc A; Mondoly P; Chiriac AM; Acket B; Zhao X; Pasquié JL; Cardin C; Delay M; Sadron M; Carrié D; Galinier M; Davy JM; Arne-Bès MC; Raczka F
    Heart Rhythm; 2014 Oct; 11(10):1721-7. PubMed ID: 25016148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges.
    Veltmann C; Wolpert C; Sacher F; Mabo P; Schimpf R; Streitner F; Brade J; Kyndt F; Kuschyk J; Le Marec H; Borggrefe M; Probst V
    Europace; 2009 Oct; 11(10):1345-52. PubMed ID: 19589796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is a drug-challenge test with propafenone adequate to exclude Brugada syndrome?
    Yildiz BS; Gungor H; Gul I; Bilgin M; Zoghi M; Akilli A
    Cardiovasc J Afr; 2013 Mar; 24(2):e4-6. PubMed ID: 23613002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.